Iterum Therapeutics plc — Director's Dealing 2018

May 30, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Iterum Therapeutics plc (ITRM)
CIK: 0001659323
Period of Report: 2018-05-30

Reporting Person: Matthews Judith M. (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-05-30	Ordinary Shares	C	10980	—	Acquired	46626	Direct
2018-05-30	Ordinary Shares	C	3038	—	Acquired	49664	Direct
2018-05-30	Ordinary Shares	C	2466	—	Acquired	52130	Direct
2018-05-30	Ordinary Shares	P	4000	$13.00	Acquired	56130	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-05-30	Series A Preferred Shares	$	C	10980	Disposed		Ordinary Shares (10980)	Direct
2018-05-30	Series B-1 Preferred Shares	$	C	3038	Disposed		Ordinary Shares (3038)	Direct
2018-05-30	Series B-2 Preferred Shares	$	C	2466	Disposed		Ordinary Shares (2466)	Direct

Footnotes

F1: The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

F2: The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

F3: The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

F4: Not applicable.